sri divya
Nansri Saha
Abstract
The present study demonstrated that Acyclovir and Omeprazole nanogel were successfully developed
by solvent diffusion method. pH was determined various formulation F1-F9 in that F9 have suitable for
gel preparation. Drug content was determined by UV-spectroscopic method. The prepared nanogel was
opaque, without any lumps, particle and aggregates. So, all the formulations are homogenous.
Spreadability diameter study F9 shown the nanogel is having good Spreadability. Nanogel formulations
shown viscosity range from 3268–3528 cps. It concluded that they are stable in nature. In-vitro
dissolution study was performed and showed that F9 have good dissolution rate. The particle size, PDI
and zeta potential to find out the F9 formulation. The particle size, PDI and zeta potential was found
to be in 687.4, 0.842 and -43.7 respectively. TEM image was confirmed the shape of spherical and
smooth surface of particles at range 650 nm. Comparing F9 nanogel formulation with acyclovir
marketed formulation (MF) by in-vitro release study. According to result formulated Acyclovir and
omeprazole nanogel is more efficient than the marketed acyclovir ointment. Hence from our study the
acyclovir and omeprazole nanogel (F9) showed that sustain drug release than the marketed
formulation, so it is evident that formulating into nanogel results increase the anti –viral activity.
Keywords: Formulation, Nano Transdermal, Acyclovir, Omeprazole, Anti-Viral Activity
[This article belongs to International Journal of Biomedical Innovations and Engineering(ijbie)]
References
1. K. S. Paudel, M. Milewski, C. L. Swadley, N. K. Brogden, P. Ghosh and A. L. Stinchcomb, Challenges and opportunities in dermal/transdermal delivery, Ther. Delivery, 2010, 1, 109 —131
2. S. Wright, M. Yelland, K. Heathcote, S. K. Ng and G. Wright, Fear of needles-nature and prevalence in general practice, Aust. Fam. Physician, 2009, 38, 172 —176
3. C. M. McMurtry, R. Pillai Riddell, A. Taddio, N. Racine, G. J. Asmundson, M. Noel, C. T. Chambers and V. Shah, HelpinKids; Adults, T., Far From “Just a Poke”: Common Painful Needle Procedures and the Development of Needle Fear, Clin. J. Pain, 2015, 31, S3 —S11
4. M. N. Pastore, Y. N. Kalia, M. Horstmann and M. S. Roberts, Transdermal patches: history, development and pharmacology, Br. J. Pharmacol., 2015, 172, 2179 —2209
5. T. Waghule, V. K. Rapalli, S. Gorantla, R. N. Saha, S. K. Dubey, A. Puri and G. Singhvi, Nanostructured Lipid Carriers as Potential Drug Delivery Systems for Skin Disorders, Curr. Pharm. Des., 2020, 26, 4569 —4579
6. S. M. Silva, L. Hu, J. J. Sousa, A. A. Pais and B. B. Michniak-Kohn, A combination of nonionic surfactants and iontophoresis to enhance the transdermal drug delivery of ondansetron HCl and diltiazem HCl, Eur. J. Pharm. Biopharm., 2012, 80, 663 —673
7. M. Pradhan, S. Srivastava, D. Singh, S. Saraf, S. Saraf and M. R. Singh, Perspectives of Lipid-Based Drug Carrier Systems for Transdermal Delivery, Crit. Rev. Ther. Drug Carrier Syst., 2018, 35, 331 —367
8. V. H. S. Araujo, L. Delello Di Filippo, J. L. Duarte, L. Sposito, B. A. F. Camargo, P. B. da Silva and M. Chorilli, Exploiting solid lipid nanoparticles and nanostructured lipid carriers for drug delivery against cutaneous fungal infections, Crit. Rev. Microbiol., 2021, 47, 79 —90
9. M. Sguizzato, E. Esposito and R. Cortesi, Lipid-Based Nanosystems as a Tool to Overcome Skin Barrier, Int. J. Mol. Sci., 2021, 22, 8319
10. M. Gupta, U. Agrawal and S. P. Vyas, Nanocarrier-based topical drug delivery for the treatment of skin diseases, Expert Opin. Drug Delivery, 2012, 9, 783 —804
11. T. Qi, B. Chen, Z. Wang, H. Du, D. Liu, Q. Yin, B. Liu, Q. Zhang and Y. Wang, A pH-Activatable nanoparticle for dual-stage precisely mitochondria-targeted photodynamic anticancer therapy, Biomaterials, 2019, 213, 119219
12. Y. Hui, X. Yi, F. Hou, D. Wibowo, F. Zhang, D. Zhao, H. Gao and C. X. Zhao, Role of Nanoparticle Mechanical Properties in Cancer Drug Delivery, ACS Nano, 2019, 13, 7410 —7424
13. G. Birrenbach and P. P. Speiser, Polymerized micelles and their use as adjuvants in immunology, J. Pharm. Sci., 1976, 65, 1763 —1766.
14. L. Yang, C. S. Kwan, L. L. Zhang, X. H. Li, Y. Han, K. C. F. Leung, Y. G. Yang and Z. F. Huang, Chiral Nanoparticle-Induced Enantioselective Amplification of Molecular Optical Activity, Adv. Funct. Mater., 2019, 29, 1807307
15. A. Shchelokov, N. Palko, V. Potemkin, M. Grishina, R. Morozov, E. Korina, D. Uchaev, I. Krivtsov and O. Bol’shakov, Adsorption of Native Amino Acids on Nanocrystalline TiO2: Physical Chemistry, QSPR, and Theoretical Modeling, Langmuir, 2019, 35, 538 —550
16. F. Rancan, H. Volkmann, M. Giulbudagian, F. Schumacher, J. I. Stanko, B. Kleuser, U. Blume-Peytavi, M. Calderon and A. Vogt, Dermal Delivery of the High-Molecular-Weight Drug Tacrolimus by Means of Polyglycerol-Based Nanogels, Pharmaceutics, 2019, 11, 394
17. F. Rancan, M. Asadian-Birjand, S. Dogan, C. Graf, L. Cuellar, S. Lommatzsch, U. Blume-Peytavi, M. Calderon and A. Vogt, Effects of thermoresponsivity and softness on skin penetration and cellular uptake of polyglycerol-based nanogels, J. Controlled Release, 2016, 228, 159 —169
18. N. Tiwari, E. R. Osorio-Blanco, A. Sonzogni, D. Esporrin-Ubieto, H. Wang and M. Calderon, Nanocarriers for Skin Applications: Where Do We Stand?, Angew. Chem., Int. Ed. Engl., 2022, 61, e202107960
19. E. Ratemi, A. Sultana Shaik, A. Al Faraj and R. Halwani, Alternative approaches for the treatment of airway diseases: focus on nanoparticle medicine, Clin. Exp. Allergy, 2016, 46, 1033 —1042
20. A. Yau, J. Lee and Y. Chen, Nanomaterials for Protein Delivery in Anticancer Applications, Pharmaceutics, 2021, 13, 155
| Volume | 02 |
| Issue | 01 |
| Received | February 8, 2024 |
| Accepted | February 11, 2024 |
| Published | April 8, 2024 |